Use of the neutrophil to lymphocyte ratio (NLR) and the platelet to lymphocyte ratio (PLR) for prognostication of patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT): a systematic review
Background and purpose The neutrophil to lymphocyte (NLR) and platelet to lymphocyte (PLR) ratios are markers of systemic inflammation with uncertain prognostic utility. Thus, we conducted a systematic review of NLR and PLR as prognostic factors for overall survival (OS), progression-free survival (...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Sit, Daegan [verfasserIn] Raissi, Thomas [verfasserIn] Giuliani, Meredith [verfasserIn] Lee, Percy [verfasserIn] Shaverdian, Narek [verfasserIn] Walker-Dilks, Cindy [verfasserIn] Swaminath, Anand [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2019 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Journal of radiation oncology - Berlin : Springer, 2012, 8(2019), 1 vom: März, Seite 13-21 |
|---|---|
| Übergeordnetes Werk: |
volume:8 ; year:2019 ; number:1 ; month:03 ; pages:13-21 |
| Links: |
|---|
| DOI / URN: |
10.1007/s13566-019-00380-4 |
|---|
| Katalog-ID: |
SPR031813283 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR031813283 | ||
| 003 | DE-627 | ||
| 005 | 20230519141843.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13566-019-00380-4 |2 doi | |
| 035 | |a (DE-627)SPR031813283 | ||
| 035 | |a (SPR)s13566-019-00380-4-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Sit, Daegan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of the neutrophil to lymphocyte ratio (NLR) and the platelet to lymphocyte ratio (PLR) for prognostication of patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT): a systematic review |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background and purpose The neutrophil to lymphocyte (NLR) and platelet to lymphocyte (PLR) ratios are markers of systemic inflammation with uncertain prognostic utility. Thus, we conducted a systematic review of NLR and PLR as prognostic factors for overall survival (OS), progression-free survival (PFS), and local control (LC) of patients with stage 1 non-small cell lung cancer (NSCLC) following stereotactic body radiotherapy (SBRT) with curative intent. Methods and materials The EMBASE, Cochrane Library, MEDLINE, and PubMed databases were searched from January 1996 until September 2017 for primary research studies and systematic literature reviews that reported pre-treatment NLR and PLR of patients with stage 1 NSCLC and OS, PFS, and/or LC of patients following SBRT. Results An electronic database search identified 292 articles, of which five were eligible for inclusion. Cutoffs for a high NLR ranged from 2.18 to 3.155 while cutoffs for a high PLR ranged from 146 to 187.27. Four studies reported outcomes related to disease control and had mixed results as to the utility of the NLR and PLR as a prognostic factor. Four studies analyzed the association between high NLR cutoff with OS and all found a statistically significant association. Three studies examined a high PLR cutoff and all found a statistically significant association with worse OS. Conclusion NLR and PLR appear to be relevant prognostic factors for OS following lung SBRT in stage I NSCLC. They may serve as accessible and inexpensive tests to aid in clinical decision-making but prospective validation is necessary. | ||
| 650 | 4 | |a Carcinoma |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Non-small cell lung |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Radiosurgery |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Radiotherapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Conformal |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Review |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Systematic |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Neutrophil to lymphocyte ratio |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Platelet to lymphocyte ratio |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Inflammation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Prognosis |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Raissi, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Giuliani, Meredith |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Percy |e verfasserin |4 aut | |
| 700 | 1 | |a Shaverdian, Narek |e verfasserin |4 aut | |
| 700 | 1 | |a Walker-Dilks, Cindy |e verfasserin |4 aut | |
| 700 | 1 | |a Swaminath, Anand |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of radiation oncology |d Berlin : Springer, 2012 |g 8(2019), 1 vom: März, Seite 13-21 |w (DE-627)718611233 |w (DE-600)2660511-9 |x 1948-7908 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2019 |g number:1 |g month:03 |g pages:13-21 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13566-019-00380-4 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_32 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_90 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_101 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_120 | ||
| 912 | |a GBV_ILN_138 | ||
| 912 | |a GBV_ILN_150 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_171 | ||
| 912 | |a GBV_ILN_187 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_224 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_250 | ||
| 912 | |a GBV_ILN_281 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_370 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_636 | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2007 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2015 | ||
| 912 | |a GBV_ILN_2020 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_2025 | ||
| 912 | |a GBV_ILN_2026 | ||
| 912 | |a GBV_ILN_2027 | ||
| 912 | |a GBV_ILN_2031 | ||
| 912 | |a GBV_ILN_2034 | ||
| 912 | |a GBV_ILN_2037 | ||
| 912 | |a GBV_ILN_2038 | ||
| 912 | |a GBV_ILN_2039 | ||
| 912 | |a GBV_ILN_2044 | ||
| 912 | |a GBV_ILN_2048 | ||
| 912 | |a GBV_ILN_2049 | ||
| 912 | |a GBV_ILN_2050 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2057 | ||
| 912 | |a GBV_ILN_2059 | ||
| 912 | |a GBV_ILN_2061 | ||
| 912 | |a GBV_ILN_2064 | ||
| 912 | |a GBV_ILN_2065 | ||
| 912 | |a GBV_ILN_2068 | ||
| 912 | |a GBV_ILN_2070 | ||
| 912 | |a GBV_ILN_2086 | ||
| 912 | |a GBV_ILN_2088 | ||
| 912 | |a GBV_ILN_2093 | ||
| 912 | |a GBV_ILN_2106 | ||
| 912 | |a GBV_ILN_2107 | ||
| 912 | |a GBV_ILN_2108 | ||
| 912 | |a GBV_ILN_2110 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_2112 | ||
| 912 | |a GBV_ILN_2113 | ||
| 912 | |a GBV_ILN_2116 | ||
| 912 | |a GBV_ILN_2118 | ||
| 912 | |a GBV_ILN_2119 | ||
| 912 | |a GBV_ILN_2122 | ||
| 912 | |a GBV_ILN_2129 | ||
| 912 | |a GBV_ILN_2143 | ||
| 912 | |a GBV_ILN_2144 | ||
| 912 | |a GBV_ILN_2147 | ||
| 912 | |a GBV_ILN_2148 | ||
| 912 | |a GBV_ILN_2152 | ||
| 912 | |a GBV_ILN_2153 | ||
| 912 | |a GBV_ILN_2188 | ||
| 912 | |a GBV_ILN_2232 | ||
| 912 | |a GBV_ILN_2336 | ||
| 912 | |a GBV_ILN_2446 | ||
| 912 | |a GBV_ILN_2470 | ||
| 912 | |a GBV_ILN_2472 | ||
| 912 | |a GBV_ILN_2507 | ||
| 912 | |a GBV_ILN_2522 | ||
| 912 | |a GBV_ILN_2548 | ||
| 912 | |a GBV_ILN_4035 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4046 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4242 | ||
| 912 | |a GBV_ILN_4246 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4251 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4326 | ||
| 912 | |a GBV_ILN_4333 | ||
| 912 | |a GBV_ILN_4334 | ||
| 912 | |a GBV_ILN_4335 | ||
| 912 | |a GBV_ILN_4336 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4393 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2019 |e 1 |c 03 |h 13-21 | ||
| author_variant |
d s ds t r tr m g mg p l pl n s ns c w d cwd a s as |
|---|---|
| matchkey_str |
article:19487908:2019----::soteetohloypoyeainrnteltltoypoyeaiproponsiainfainsihalsaeosalelugacrsltetdih |
| hierarchy_sort_str |
2019 |
| publishDate |
2019 |
| allfields |
10.1007/s13566-019-00380-4 doi (DE-627)SPR031813283 (SPR)s13566-019-00380-4-e DE-627 ger DE-627 rakwb eng 610 ASE Sit, Daegan verfasserin aut Use of the neutrophil to lymphocyte ratio (NLR) and the platelet to lymphocyte ratio (PLR) for prognostication of patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT): a systematic review 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background and purpose The neutrophil to lymphocyte (NLR) and platelet to lymphocyte (PLR) ratios are markers of systemic inflammation with uncertain prognostic utility. Thus, we conducted a systematic review of NLR and PLR as prognostic factors for overall survival (OS), progression-free survival (PFS), and local control (LC) of patients with stage 1 non-small cell lung cancer (NSCLC) following stereotactic body radiotherapy (SBRT) with curative intent. Methods and materials The EMBASE, Cochrane Library, MEDLINE, and PubMed databases were searched from January 1996 until September 2017 for primary research studies and systematic literature reviews that reported pre-treatment NLR and PLR of patients with stage 1 NSCLC and OS, PFS, and/or LC of patients following SBRT. Results An electronic database search identified 292 articles, of which five were eligible for inclusion. Cutoffs for a high NLR ranged from 2.18 to 3.155 while cutoffs for a high PLR ranged from 146 to 187.27. Four studies reported outcomes related to disease control and had mixed results as to the utility of the NLR and PLR as a prognostic factor. Four studies analyzed the association between high NLR cutoff with OS and all found a statistically significant association. Three studies examined a high PLR cutoff and all found a statistically significant association with worse OS. Conclusion NLR and PLR appear to be relevant prognostic factors for OS following lung SBRT in stage I NSCLC. They may serve as accessible and inexpensive tests to aid in clinical decision-making but prospective validation is necessary. Carcinoma (dpeaa)DE-He213 Non-small cell lung (dpeaa)DE-He213 Radiosurgery (dpeaa)DE-He213 Radiotherapy (dpeaa)DE-He213 Conformal (dpeaa)DE-He213 Review (dpeaa)DE-He213 Systematic (dpeaa)DE-He213 Neutrophil to lymphocyte ratio (dpeaa)DE-He213 Platelet to lymphocyte ratio (dpeaa)DE-He213 Inflammation (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213 Raissi, Thomas verfasserin aut Giuliani, Meredith verfasserin aut Lee, Percy verfasserin aut Shaverdian, Narek verfasserin aut Walker-Dilks, Cindy verfasserin aut Swaminath, Anand verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 8(2019), 1 vom: März, Seite 13-21 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:8 year:2019 number:1 month:03 pages:13-21 https://dx.doi.org/10.1007/s13566-019-00380-4 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 8 2019 1 03 13-21 |
| spelling |
10.1007/s13566-019-00380-4 doi (DE-627)SPR031813283 (SPR)s13566-019-00380-4-e DE-627 ger DE-627 rakwb eng 610 ASE Sit, Daegan verfasserin aut Use of the neutrophil to lymphocyte ratio (NLR) and the platelet to lymphocyte ratio (PLR) for prognostication of patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT): a systematic review 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background and purpose The neutrophil to lymphocyte (NLR) and platelet to lymphocyte (PLR) ratios are markers of systemic inflammation with uncertain prognostic utility. Thus, we conducted a systematic review of NLR and PLR as prognostic factors for overall survival (OS), progression-free survival (PFS), and local control (LC) of patients with stage 1 non-small cell lung cancer (NSCLC) following stereotactic body radiotherapy (SBRT) with curative intent. Methods and materials The EMBASE, Cochrane Library, MEDLINE, and PubMed databases were searched from January 1996 until September 2017 for primary research studies and systematic literature reviews that reported pre-treatment NLR and PLR of patients with stage 1 NSCLC and OS, PFS, and/or LC of patients following SBRT. Results An electronic database search identified 292 articles, of which five were eligible for inclusion. Cutoffs for a high NLR ranged from 2.18 to 3.155 while cutoffs for a high PLR ranged from 146 to 187.27. Four studies reported outcomes related to disease control and had mixed results as to the utility of the NLR and PLR as a prognostic factor. Four studies analyzed the association between high NLR cutoff with OS and all found a statistically significant association. Three studies examined a high PLR cutoff and all found a statistically significant association with worse OS. Conclusion NLR and PLR appear to be relevant prognostic factors for OS following lung SBRT in stage I NSCLC. They may serve as accessible and inexpensive tests to aid in clinical decision-making but prospective validation is necessary. Carcinoma (dpeaa)DE-He213 Non-small cell lung (dpeaa)DE-He213 Radiosurgery (dpeaa)DE-He213 Radiotherapy (dpeaa)DE-He213 Conformal (dpeaa)DE-He213 Review (dpeaa)DE-He213 Systematic (dpeaa)DE-He213 Neutrophil to lymphocyte ratio (dpeaa)DE-He213 Platelet to lymphocyte ratio (dpeaa)DE-He213 Inflammation (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213 Raissi, Thomas verfasserin aut Giuliani, Meredith verfasserin aut Lee, Percy verfasserin aut Shaverdian, Narek verfasserin aut Walker-Dilks, Cindy verfasserin aut Swaminath, Anand verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 8(2019), 1 vom: März, Seite 13-21 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:8 year:2019 number:1 month:03 pages:13-21 https://dx.doi.org/10.1007/s13566-019-00380-4 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 8 2019 1 03 13-21 |
| allfields_unstemmed |
10.1007/s13566-019-00380-4 doi (DE-627)SPR031813283 (SPR)s13566-019-00380-4-e DE-627 ger DE-627 rakwb eng 610 ASE Sit, Daegan verfasserin aut Use of the neutrophil to lymphocyte ratio (NLR) and the platelet to lymphocyte ratio (PLR) for prognostication of patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT): a systematic review 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background and purpose The neutrophil to lymphocyte (NLR) and platelet to lymphocyte (PLR) ratios are markers of systemic inflammation with uncertain prognostic utility. Thus, we conducted a systematic review of NLR and PLR as prognostic factors for overall survival (OS), progression-free survival (PFS), and local control (LC) of patients with stage 1 non-small cell lung cancer (NSCLC) following stereotactic body radiotherapy (SBRT) with curative intent. Methods and materials The EMBASE, Cochrane Library, MEDLINE, and PubMed databases were searched from January 1996 until September 2017 for primary research studies and systematic literature reviews that reported pre-treatment NLR and PLR of patients with stage 1 NSCLC and OS, PFS, and/or LC of patients following SBRT. Results An electronic database search identified 292 articles, of which five were eligible for inclusion. Cutoffs for a high NLR ranged from 2.18 to 3.155 while cutoffs for a high PLR ranged from 146 to 187.27. Four studies reported outcomes related to disease control and had mixed results as to the utility of the NLR and PLR as a prognostic factor. Four studies analyzed the association between high NLR cutoff with OS and all found a statistically significant association. Three studies examined a high PLR cutoff and all found a statistically significant association with worse OS. Conclusion NLR and PLR appear to be relevant prognostic factors for OS following lung SBRT in stage I NSCLC. They may serve as accessible and inexpensive tests to aid in clinical decision-making but prospective validation is necessary. Carcinoma (dpeaa)DE-He213 Non-small cell lung (dpeaa)DE-He213 Radiosurgery (dpeaa)DE-He213 Radiotherapy (dpeaa)DE-He213 Conformal (dpeaa)DE-He213 Review (dpeaa)DE-He213 Systematic (dpeaa)DE-He213 Neutrophil to lymphocyte ratio (dpeaa)DE-He213 Platelet to lymphocyte ratio (dpeaa)DE-He213 Inflammation (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213 Raissi, Thomas verfasserin aut Giuliani, Meredith verfasserin aut Lee, Percy verfasserin aut Shaverdian, Narek verfasserin aut Walker-Dilks, Cindy verfasserin aut Swaminath, Anand verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 8(2019), 1 vom: März, Seite 13-21 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:8 year:2019 number:1 month:03 pages:13-21 https://dx.doi.org/10.1007/s13566-019-00380-4 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 8 2019 1 03 13-21 |
| allfieldsGer |
10.1007/s13566-019-00380-4 doi (DE-627)SPR031813283 (SPR)s13566-019-00380-4-e DE-627 ger DE-627 rakwb eng 610 ASE Sit, Daegan verfasserin aut Use of the neutrophil to lymphocyte ratio (NLR) and the platelet to lymphocyte ratio (PLR) for prognostication of patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT): a systematic review 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background and purpose The neutrophil to lymphocyte (NLR) and platelet to lymphocyte (PLR) ratios are markers of systemic inflammation with uncertain prognostic utility. Thus, we conducted a systematic review of NLR and PLR as prognostic factors for overall survival (OS), progression-free survival (PFS), and local control (LC) of patients with stage 1 non-small cell lung cancer (NSCLC) following stereotactic body radiotherapy (SBRT) with curative intent. Methods and materials The EMBASE, Cochrane Library, MEDLINE, and PubMed databases were searched from January 1996 until September 2017 for primary research studies and systematic literature reviews that reported pre-treatment NLR and PLR of patients with stage 1 NSCLC and OS, PFS, and/or LC of patients following SBRT. Results An electronic database search identified 292 articles, of which five were eligible for inclusion. Cutoffs for a high NLR ranged from 2.18 to 3.155 while cutoffs for a high PLR ranged from 146 to 187.27. Four studies reported outcomes related to disease control and had mixed results as to the utility of the NLR and PLR as a prognostic factor. Four studies analyzed the association between high NLR cutoff with OS and all found a statistically significant association. Three studies examined a high PLR cutoff and all found a statistically significant association with worse OS. Conclusion NLR and PLR appear to be relevant prognostic factors for OS following lung SBRT in stage I NSCLC. They may serve as accessible and inexpensive tests to aid in clinical decision-making but prospective validation is necessary. Carcinoma (dpeaa)DE-He213 Non-small cell lung (dpeaa)DE-He213 Radiosurgery (dpeaa)DE-He213 Radiotherapy (dpeaa)DE-He213 Conformal (dpeaa)DE-He213 Review (dpeaa)DE-He213 Systematic (dpeaa)DE-He213 Neutrophil to lymphocyte ratio (dpeaa)DE-He213 Platelet to lymphocyte ratio (dpeaa)DE-He213 Inflammation (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213 Raissi, Thomas verfasserin aut Giuliani, Meredith verfasserin aut Lee, Percy verfasserin aut Shaverdian, Narek verfasserin aut Walker-Dilks, Cindy verfasserin aut Swaminath, Anand verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 8(2019), 1 vom: März, Seite 13-21 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:8 year:2019 number:1 month:03 pages:13-21 https://dx.doi.org/10.1007/s13566-019-00380-4 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 8 2019 1 03 13-21 |
| allfieldsSound |
10.1007/s13566-019-00380-4 doi (DE-627)SPR031813283 (SPR)s13566-019-00380-4-e DE-627 ger DE-627 rakwb eng 610 ASE Sit, Daegan verfasserin aut Use of the neutrophil to lymphocyte ratio (NLR) and the platelet to lymphocyte ratio (PLR) for prognostication of patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT): a systematic review 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background and purpose The neutrophil to lymphocyte (NLR) and platelet to lymphocyte (PLR) ratios are markers of systemic inflammation with uncertain prognostic utility. Thus, we conducted a systematic review of NLR and PLR as prognostic factors for overall survival (OS), progression-free survival (PFS), and local control (LC) of patients with stage 1 non-small cell lung cancer (NSCLC) following stereotactic body radiotherapy (SBRT) with curative intent. Methods and materials The EMBASE, Cochrane Library, MEDLINE, and PubMed databases were searched from January 1996 until September 2017 for primary research studies and systematic literature reviews that reported pre-treatment NLR and PLR of patients with stage 1 NSCLC and OS, PFS, and/or LC of patients following SBRT. Results An electronic database search identified 292 articles, of which five were eligible for inclusion. Cutoffs for a high NLR ranged from 2.18 to 3.155 while cutoffs for a high PLR ranged from 146 to 187.27. Four studies reported outcomes related to disease control and had mixed results as to the utility of the NLR and PLR as a prognostic factor. Four studies analyzed the association between high NLR cutoff with OS and all found a statistically significant association. Three studies examined a high PLR cutoff and all found a statistically significant association with worse OS. Conclusion NLR and PLR appear to be relevant prognostic factors for OS following lung SBRT in stage I NSCLC. They may serve as accessible and inexpensive tests to aid in clinical decision-making but prospective validation is necessary. Carcinoma (dpeaa)DE-He213 Non-small cell lung (dpeaa)DE-He213 Radiosurgery (dpeaa)DE-He213 Radiotherapy (dpeaa)DE-He213 Conformal (dpeaa)DE-He213 Review (dpeaa)DE-He213 Systematic (dpeaa)DE-He213 Neutrophil to lymphocyte ratio (dpeaa)DE-He213 Platelet to lymphocyte ratio (dpeaa)DE-He213 Inflammation (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213 Raissi, Thomas verfasserin aut Giuliani, Meredith verfasserin aut Lee, Percy verfasserin aut Shaverdian, Narek verfasserin aut Walker-Dilks, Cindy verfasserin aut Swaminath, Anand verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 8(2019), 1 vom: März, Seite 13-21 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:8 year:2019 number:1 month:03 pages:13-21 https://dx.doi.org/10.1007/s13566-019-00380-4 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 8 2019 1 03 13-21 |
| language |
English |
| source |
Enthalten in Journal of radiation oncology 8(2019), 1 vom: März, Seite 13-21 volume:8 year:2019 number:1 month:03 pages:13-21 |
| sourceStr |
Enthalten in Journal of radiation oncology 8(2019), 1 vom: März, Seite 13-21 volume:8 year:2019 number:1 month:03 pages:13-21 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Carcinoma Non-small cell lung Radiosurgery Radiotherapy Conformal Review Systematic Neutrophil to lymphocyte ratio Platelet to lymphocyte ratio Inflammation Prognosis |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Journal of radiation oncology |
| authorswithroles_txt_mv |
Sit, Daegan @@aut@@ Raissi, Thomas @@aut@@ Giuliani, Meredith @@aut@@ Lee, Percy @@aut@@ Shaverdian, Narek @@aut@@ Walker-Dilks, Cindy @@aut@@ Swaminath, Anand @@aut@@ |
| publishDateDaySort_date |
2019-03-01T00:00:00Z |
| hierarchy_top_id |
718611233 |
| dewey-sort |
3610 |
| id |
SPR031813283 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR031813283</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519141843.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13566-019-00380-4</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR031813283</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13566-019-00380-4-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sit, Daegan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Use of the neutrophil to lymphocyte ratio (NLR) and the platelet to lymphocyte ratio (PLR) for prognostication of patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT): a systematic review</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background and purpose The neutrophil to lymphocyte (NLR) and platelet to lymphocyte (PLR) ratios are markers of systemic inflammation with uncertain prognostic utility. Thus, we conducted a systematic review of NLR and PLR as prognostic factors for overall survival (OS), progression-free survival (PFS), and local control (LC) of patients with stage 1 non-small cell lung cancer (NSCLC) following stereotactic body radiotherapy (SBRT) with curative intent. Methods and materials The EMBASE, Cochrane Library, MEDLINE, and PubMed databases were searched from January 1996 until September 2017 for primary research studies and systematic literature reviews that reported pre-treatment NLR and PLR of patients with stage 1 NSCLC and OS, PFS, and/or LC of patients following SBRT. Results An electronic database search identified 292 articles, of which five were eligible for inclusion. Cutoffs for a high NLR ranged from 2.18 to 3.155 while cutoffs for a high PLR ranged from 146 to 187.27. Four studies reported outcomes related to disease control and had mixed results as to the utility of the NLR and PLR as a prognostic factor. Four studies analyzed the association between high NLR cutoff with OS and all found a statistically significant association. Three studies examined a high PLR cutoff and all found a statistically significant association with worse OS. Conclusion NLR and PLR appear to be relevant prognostic factors for OS following lung SBRT in stage I NSCLC. They may serve as accessible and inexpensive tests to aid in clinical decision-making but prospective validation is necessary.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Carcinoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Non-small cell lung</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Radiosurgery</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Radiotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Conformal</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Review</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Systematic</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neutrophil to lymphocyte ratio</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Platelet to lymphocyte ratio</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Inflammation</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prognosis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Raissi, Thomas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Giuliani, Meredith</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, Percy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shaverdian, Narek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Walker-Dilks, Cindy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Swaminath, Anand</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of radiation oncology</subfield><subfield code="d">Berlin : Springer, 2012</subfield><subfield code="g">8(2019), 1 vom: März, Seite 13-21</subfield><subfield code="w">(DE-627)718611233</subfield><subfield code="w">(DE-600)2660511-9</subfield><subfield code="x">1948-7908</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:1</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:13-21</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13566-019-00380-4</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2019</subfield><subfield code="e">1</subfield><subfield code="c">03</subfield><subfield code="h">13-21</subfield></datafield></record></collection>
|
| author |
Sit, Daegan |
| spellingShingle |
Sit, Daegan ddc 610 misc Carcinoma misc Non-small cell lung misc Radiosurgery misc Radiotherapy misc Conformal misc Review misc Systematic misc Neutrophil to lymphocyte ratio misc Platelet to lymphocyte ratio misc Inflammation misc Prognosis Use of the neutrophil to lymphocyte ratio (NLR) and the platelet to lymphocyte ratio (PLR) for prognostication of patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT): a systematic review |
| authorStr |
Sit, Daegan |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)718611233 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1948-7908 |
| topic_title |
610 ASE Use of the neutrophil to lymphocyte ratio (NLR) and the platelet to lymphocyte ratio (PLR) for prognostication of patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT): a systematic review Carcinoma (dpeaa)DE-He213 Non-small cell lung (dpeaa)DE-He213 Radiosurgery (dpeaa)DE-He213 Radiotherapy (dpeaa)DE-He213 Conformal (dpeaa)DE-He213 Review (dpeaa)DE-He213 Systematic (dpeaa)DE-He213 Neutrophil to lymphocyte ratio (dpeaa)DE-He213 Platelet to lymphocyte ratio (dpeaa)DE-He213 Inflammation (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213 |
| topic |
ddc 610 misc Carcinoma misc Non-small cell lung misc Radiosurgery misc Radiotherapy misc Conformal misc Review misc Systematic misc Neutrophil to lymphocyte ratio misc Platelet to lymphocyte ratio misc Inflammation misc Prognosis |
| topic_unstemmed |
ddc 610 misc Carcinoma misc Non-small cell lung misc Radiosurgery misc Radiotherapy misc Conformal misc Review misc Systematic misc Neutrophil to lymphocyte ratio misc Platelet to lymphocyte ratio misc Inflammation misc Prognosis |
| topic_browse |
ddc 610 misc Carcinoma misc Non-small cell lung misc Radiosurgery misc Radiotherapy misc Conformal misc Review misc Systematic misc Neutrophil to lymphocyte ratio misc Platelet to lymphocyte ratio misc Inflammation misc Prognosis |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Journal of radiation oncology |
| hierarchy_parent_id |
718611233 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Journal of radiation oncology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)718611233 (DE-600)2660511-9 |
| title |
Use of the neutrophil to lymphocyte ratio (NLR) and the platelet to lymphocyte ratio (PLR) for prognostication of patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT): a systematic review |
| ctrlnum |
(DE-627)SPR031813283 (SPR)s13566-019-00380-4-e |
| title_full |
Use of the neutrophil to lymphocyte ratio (NLR) and the platelet to lymphocyte ratio (PLR) for prognostication of patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT): a systematic review |
| author_sort |
Sit, Daegan |
| journal |
Journal of radiation oncology |
| journalStr |
Journal of radiation oncology |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
txt |
| container_start_page |
13 |
| author_browse |
Sit, Daegan Raissi, Thomas Giuliani, Meredith Lee, Percy Shaverdian, Narek Walker-Dilks, Cindy Swaminath, Anand |
| container_volume |
8 |
| class |
610 ASE |
| format_se |
Elektronische Aufsätze |
| author-letter |
Sit, Daegan |
| doi_str_mv |
10.1007/s13566-019-00380-4 |
| dewey-full |
610 |
| author2-role |
verfasserin |
| title_sort |
use of the neutrophil to lymphocyte ratio (nlr) and the platelet to lymphocyte ratio (plr) for prognostication of patients with early-stage non-small cell lung cancer (nsclc) treated with stereotactic body radiation therapy (sbrt): a systematic review |
| title_auth |
Use of the neutrophil to lymphocyte ratio (NLR) and the platelet to lymphocyte ratio (PLR) for prognostication of patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT): a systematic review |
| abstract |
Background and purpose The neutrophil to lymphocyte (NLR) and platelet to lymphocyte (PLR) ratios are markers of systemic inflammation with uncertain prognostic utility. Thus, we conducted a systematic review of NLR and PLR as prognostic factors for overall survival (OS), progression-free survival (PFS), and local control (LC) of patients with stage 1 non-small cell lung cancer (NSCLC) following stereotactic body radiotherapy (SBRT) with curative intent. Methods and materials The EMBASE, Cochrane Library, MEDLINE, and PubMed databases were searched from January 1996 until September 2017 for primary research studies and systematic literature reviews that reported pre-treatment NLR and PLR of patients with stage 1 NSCLC and OS, PFS, and/or LC of patients following SBRT. Results An electronic database search identified 292 articles, of which five were eligible for inclusion. Cutoffs for a high NLR ranged from 2.18 to 3.155 while cutoffs for a high PLR ranged from 146 to 187.27. Four studies reported outcomes related to disease control and had mixed results as to the utility of the NLR and PLR as a prognostic factor. Four studies analyzed the association between high NLR cutoff with OS and all found a statistically significant association. Three studies examined a high PLR cutoff and all found a statistically significant association with worse OS. Conclusion NLR and PLR appear to be relevant prognostic factors for OS following lung SBRT in stage I NSCLC. They may serve as accessible and inexpensive tests to aid in clinical decision-making but prospective validation is necessary. |
| abstractGer |
Background and purpose The neutrophil to lymphocyte (NLR) and platelet to lymphocyte (PLR) ratios are markers of systemic inflammation with uncertain prognostic utility. Thus, we conducted a systematic review of NLR and PLR as prognostic factors for overall survival (OS), progression-free survival (PFS), and local control (LC) of patients with stage 1 non-small cell lung cancer (NSCLC) following stereotactic body radiotherapy (SBRT) with curative intent. Methods and materials The EMBASE, Cochrane Library, MEDLINE, and PubMed databases were searched from January 1996 until September 2017 for primary research studies and systematic literature reviews that reported pre-treatment NLR and PLR of patients with stage 1 NSCLC and OS, PFS, and/or LC of patients following SBRT. Results An electronic database search identified 292 articles, of which five were eligible for inclusion. Cutoffs for a high NLR ranged from 2.18 to 3.155 while cutoffs for a high PLR ranged from 146 to 187.27. Four studies reported outcomes related to disease control and had mixed results as to the utility of the NLR and PLR as a prognostic factor. Four studies analyzed the association between high NLR cutoff with OS and all found a statistically significant association. Three studies examined a high PLR cutoff and all found a statistically significant association with worse OS. Conclusion NLR and PLR appear to be relevant prognostic factors for OS following lung SBRT in stage I NSCLC. They may serve as accessible and inexpensive tests to aid in clinical decision-making but prospective validation is necessary. |
| abstract_unstemmed |
Background and purpose The neutrophil to lymphocyte (NLR) and platelet to lymphocyte (PLR) ratios are markers of systemic inflammation with uncertain prognostic utility. Thus, we conducted a systematic review of NLR and PLR as prognostic factors for overall survival (OS), progression-free survival (PFS), and local control (LC) of patients with stage 1 non-small cell lung cancer (NSCLC) following stereotactic body radiotherapy (SBRT) with curative intent. Methods and materials The EMBASE, Cochrane Library, MEDLINE, and PubMed databases were searched from January 1996 until September 2017 for primary research studies and systematic literature reviews that reported pre-treatment NLR and PLR of patients with stage 1 NSCLC and OS, PFS, and/or LC of patients following SBRT. Results An electronic database search identified 292 articles, of which five were eligible for inclusion. Cutoffs for a high NLR ranged from 2.18 to 3.155 while cutoffs for a high PLR ranged from 146 to 187.27. Four studies reported outcomes related to disease control and had mixed results as to the utility of the NLR and PLR as a prognostic factor. Four studies analyzed the association between high NLR cutoff with OS and all found a statistically significant association. Three studies examined a high PLR cutoff and all found a statistically significant association with worse OS. Conclusion NLR and PLR appear to be relevant prognostic factors for OS following lung SBRT in stage I NSCLC. They may serve as accessible and inexpensive tests to aid in clinical decision-making but prospective validation is necessary. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 |
| container_issue |
1 |
| title_short |
Use of the neutrophil to lymphocyte ratio (NLR) and the platelet to lymphocyte ratio (PLR) for prognostication of patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT): a systematic review |
| url |
https://dx.doi.org/10.1007/s13566-019-00380-4 |
| remote_bool |
true |
| author2 |
Raissi, Thomas Giuliani, Meredith Lee, Percy Shaverdian, Narek Walker-Dilks, Cindy Swaminath, Anand |
| author2Str |
Raissi, Thomas Giuliani, Meredith Lee, Percy Shaverdian, Narek Walker-Dilks, Cindy Swaminath, Anand |
| ppnlink |
718611233 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s13566-019-00380-4 |
| up_date |
2024-07-04T01:21:21.263Z |
| _version_ |
1803609525477965824 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR031813283</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519141843.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13566-019-00380-4</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR031813283</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13566-019-00380-4-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sit, Daegan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Use of the neutrophil to lymphocyte ratio (NLR) and the platelet to lymphocyte ratio (PLR) for prognostication of patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT): a systematic review</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background and purpose The neutrophil to lymphocyte (NLR) and platelet to lymphocyte (PLR) ratios are markers of systemic inflammation with uncertain prognostic utility. Thus, we conducted a systematic review of NLR and PLR as prognostic factors for overall survival (OS), progression-free survival (PFS), and local control (LC) of patients with stage 1 non-small cell lung cancer (NSCLC) following stereotactic body radiotherapy (SBRT) with curative intent. Methods and materials The EMBASE, Cochrane Library, MEDLINE, and PubMed databases were searched from January 1996 until September 2017 for primary research studies and systematic literature reviews that reported pre-treatment NLR and PLR of patients with stage 1 NSCLC and OS, PFS, and/or LC of patients following SBRT. Results An electronic database search identified 292 articles, of which five were eligible for inclusion. Cutoffs for a high NLR ranged from 2.18 to 3.155 while cutoffs for a high PLR ranged from 146 to 187.27. Four studies reported outcomes related to disease control and had mixed results as to the utility of the NLR and PLR as a prognostic factor. Four studies analyzed the association between high NLR cutoff with OS and all found a statistically significant association. Three studies examined a high PLR cutoff and all found a statistically significant association with worse OS. Conclusion NLR and PLR appear to be relevant prognostic factors for OS following lung SBRT in stage I NSCLC. They may serve as accessible and inexpensive tests to aid in clinical decision-making but prospective validation is necessary.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Carcinoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Non-small cell lung</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Radiosurgery</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Radiotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Conformal</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Review</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Systematic</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neutrophil to lymphocyte ratio</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Platelet to lymphocyte ratio</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Inflammation</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prognosis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Raissi, Thomas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Giuliani, Meredith</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, Percy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shaverdian, Narek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Walker-Dilks, Cindy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Swaminath, Anand</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of radiation oncology</subfield><subfield code="d">Berlin : Springer, 2012</subfield><subfield code="g">8(2019), 1 vom: März, Seite 13-21</subfield><subfield code="w">(DE-627)718611233</subfield><subfield code="w">(DE-600)2660511-9</subfield><subfield code="x">1948-7908</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:1</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:13-21</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13566-019-00380-4</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2019</subfield><subfield code="e">1</subfield><subfield code="c">03</subfield><subfield code="h">13-21</subfield></datafield></record></collection>
|
| score |
7.3992662 |